AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03303677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Nasal
Description: topical nasal saline rinses
Study NCT03960866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate Ophthalmic Solution 1%
Description: Topical Sterile Ophthalmic Solution
Study NCT03960866 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Description: Topical Sterile Ophthalmic Solution
Study NCT03275259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THORK Shock Wave® (Extracorporeal shock waves)
Description: Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
Study NCT01864876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-AF
Description: Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
Study NCT01864876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE
Description: Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
Study NCT01864876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EM060G (SE)
Description: The same stable oil-in-water emulsion (SE), but without GLA.
Study NCT03303677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Nasal
Description: saline + budesonide nasal saline irrigation
Study NCT03303677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Antibacterial (Product)
Description: The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
Study NCT00708721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
Study NCT04763655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical and neuropsychological testing
Description: Patients are monitored with Brief Psychiatric Rating Scale (BPRS) weekly and structural and functional MRI and MATRICS battery before and at the end of the course of the study
Study NCT01405417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Peroral Myotomy
Description: Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
Study NCT01323595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg PO BID x 6 days
Study NCT01323595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill PO BID x 6 days
Study NCT02340260 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High intensity interval training
Description: High intensity exercise during 12 weeks with three weekly training sessions
Study NCT02340260 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sprint interval training
Description: Sprint interval exercise during 12 weeks with three weekly training sessions
Study NCT02715505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood transplantation with HSC835
Description: Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
Study NCT00387751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00387751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00387751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00387751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given orally
Study NCT00743730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain and standard side effect management for PNCA with basal method.
Description: Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure.
Study NCT00743730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain and standard side effect management with PNCA without basal
Description: Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure.
Study NCT00743730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain and standard side effect management with IV on an as needed basis method.
Description: Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol.
Study NCT03509428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SRETP
Description: SRETP will involve short periods of exercise at a high intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session. Exercise intensities during the interval exercise-training program are specific to each patient and derived from CPET. Moderate intensity exercise is below the anaerobic threshold (AT). Patients will exercise at 80% of oxygen uptake (VO2) obtained at the anaerobic threshold (80%AT) for moderate intensity exercise - 3 minutes. Severe exercise intensity is recognised as 50% of the difference between the VO2 AT and VO2 Peak (50%∆) - 2 minutes.
Study NCT03509428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: Support sessions will be patient-centred, giving the patient an opportunity to raise any issues/concerns they are having, this may include (but will not be limited to) ways of coping with their reactions to cancer, family and relationship issues, exploring personal issues and dealing with practical issues. Patients will have access to other resources available at the cancer centres including but not restricted to further information about their condition and how to access financial support. These processes reflect the best practice currently being delivered by cancer support centre staff in the Wessex region. Any patient deemed at risk (i.e. from suicidal ideation or self harm) will be reported to their GP, followed up by a letter.
Study NCT01246037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
Study NCT01220765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography
Description: In the capnography arm, respiratory monitoring is performed with pulse oximetry and capnography. If the capnogram indicates sub-optimal ventilation and/or apnea, denoted as a flat line on the capnometer for ≥ 15 seconds, a respiratory rate ≤ 6, or a end-tidal CO2 > 50 mmHg, medical staff will intervene by arousing the patient, performing chinlift or jawthrust, abandon from giving additional propofol, or provision of oxygen. The nurse qualified in sedation management will assess capnography him/ herself.
Study NCT01865669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin, 10-10mol/L to 10-5mol/L
Study NCT04586738 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-perforating deep sclerectomy surgery
Description: Non-penetrating deep sclerectomy is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma.This surgery is performed to facilitate the outflow of aqueous humour from the anterior chamber to the subconjunctival space through a natural membrane (trabeculo-Descemet's window). This enables a more physiological reduction of intraocular pressure to be achieved.
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-903452
Description: Solution, Oral, 0.1 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-903452
Description: Solution, Oral, 0.6 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-903452
Description: Suspension, Oral, 3.0 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-903452
Description: Suspension, Oral, 10 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-903452
Description: Suspension, Oral, 30 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-903452
Description: Suspension, Oral, 60 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-903452
Description: Suspension, Oral, 120 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution, Oral, 0 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Suspension, Oral, 0 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-903452
Description: Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-903452
Description: Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
Study NCT01240980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
Study NCT04015076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inzomelid
Description: Active Drug
Study NCT04015076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match
Study NCT01913431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baracle Tab.®
Study NCT01913431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baraclude Tab.®
Study NCT03534765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT abdomen +/- pelvis
Description: Diagnostic CT scan (only if requested by responsible clinicians)
Study NCT03534765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Edmunton Frailty Score
Description: Patient completed previously valided questionnaire quantifying frailty.
Study NCT03534765 — intervention group
Intervention type: PROCEDURE
Intervention: Emergency laparotomy for general surgical pathology
Description: Emergency general surgical laparotomy (defined by the UK NELA body)
Study NCT01392222 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: The focus groups will cover the following issues~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option
Study NCT01392222 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: The focus groups will cover the following issues:~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option
Study NCT04692844 — intervention group
Intervention type: DRUG
Intervention: Propranolol
Description: Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
Study NCT04692844 — intervention group
Intervention type: DRUG
Intervention: Primidone
Description: Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
Study NCT03218332 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers for detecting possible CTE invivo
Description: Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
Study NCT03048084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Antiepileptic drug levetiracetam
Study NCT03048084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: Antiepileptic drug valproic acid
Study NCT02532959 — intervention group
Intervention type: DEVICE
Intervention: Diagnostic Breath Analysis
Description: Conduct exhaled breath samples
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-operative assessment, counseling and education
Description: pre-operative assessment, counseling and FT management education
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional drink up to 4 h prior to surgery
Description: Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bowel preparation
Description: patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative treatment with carbohydrates
Description: preoperative treatment with carbohydrates (patients without diabetes).
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fast solid
Description: fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: avoiding hypothermia
Description: avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative glycaemic control
Description: Postoperative glycaemic control;
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: postoperative nausea and vomiting (PONV) control;
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early postoperative diet
Description: early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pre-operative fasting at least 8h
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bowel preparation for traditional surgery
Description: Oral bowel preparations or mechanical bowl until liquid stool
Study NCT02687412 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: began to take solid diet after anal exhaust
Description: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
Study NCT04071977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined antioxidant therapy
Description: It consists of a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1 mg), vitamin C (L-ascorbic acid 180 mg), vitamin E (DL-alpha tocopherol 30 mg), zinc (zinc oxide 20 mg), copper (copper sulfate 1 mg), taken once a day for 12 months
Study NCT04071977 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It consists in a capsule with 100 mg of magnesium oxide
Study NCT02931890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 3 weekly course of docetaxel i.v in arm 1 and 2
Study NCT02931890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
Study NCT02931890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral capecitabine in arm 1 and 2
Study NCT02931890 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastrectomy
Description: resection of gastric cancer after pre-operative chemotherapy for all arms
Study NCT02931890 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy of gastric cancer
Description: 5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
Study NCT02931890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
Study NCT02931890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: 5 weeks of carboplatin i.v once a week (in arm 2 and 3)
Study NCT02354924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity soft contact lens
Description: Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
Study NCT02354924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visco soft contact lens
Description: Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
Study NCT03707444 — intervention group
Intervention type: DEVICE
Intervention: Scrambler Therapy Device
Description: Superficial neuromodulation using EKG type electrodes \[Scrambler (MC5-A Calmare) Therapy\]
Study NCT00657514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: 500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
Study NCT00657514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet po bid up to 2 tablets po bid if tolerated
Study NCT00235443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
Study NCT01643941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine low dose
Description: Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
Study NCT01643941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
Study NCT01643941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonization swab sample
Description: Colonization swabs will be collected from all subjects at various timepoints.
Study NCT01643941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine mid dose
Description: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
Study NCT01643941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine high dose
Description: Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
Study NCT01643941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine
Description: Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
Study NCT01643941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood for immunogenicity will be collected from all subjects at various timepoints.